Identification of genome-wide non-canonical spliced regions and analysis of biological functions for spliced sequences using Read-Split-Fly

Background It is generally thought that most canonical or non-canonical splicing events involving U2- and U12 spliceosomes occur within nuclear pre-mRNAs. However, the question of whether at least some U12-type splicing occurs in the cytoplasm is still unclear. In recent years next-generation sequencing technologies have revolutionized the field. The “Read-Split-Walk” (RSW) and “Read-Split-Run” (RSR) methods were developed to identify genome-wide non-canonical spliced regions including special events occurring in cytoplasm. As the significant amount of genome/transcriptome data such as, Encyclopedia of DNA Elements (ENCODE) project, have been generated, we have advanced a newer more memory-efficient version of the algorithm, “Read-Split-Fly” (RSF), which can detect non-canonical spliced regions with higher sensitivity and improved speed. The RSF algorithm also outputs the spliced sequences for further downstream biological function analysis. Results We used open access ENCODE project RNA-Seq data to search spliced intron sequences against the U12-type spliced intron sequence database to examine whether some events could occur as potential signatures of U12-type splicing. The check was performed by searching spliced sequences against 5’ss and 3’ss sequences from the well-known orthologous U12-type spliceosomal intron database U12DB. Preliminary results of searching 70 ENCODE samples indicated that the presence of 5’ss with U12-type signature is more frequent than U2-type and prevalent in non-canonical junctions reported by RSF. The selected spliced sequences have also been further studied using miRBase to elucidate their functionality. Preliminary results from 70 samples of ENCODE datasets show that several miRNAs are prevalent in studied ENCODE samples. Two of these are associated with many diseases as suggested in the literature. Specifically, hsa-miR-1273 and hsa-miR-548 are associated with many diseases and cancers. Conclusions Our RSF pipeline is able to detect many possible junctions (especially those with a high RPKM) with very high overall accuracy and relative high accuracy for novel junctions. We have incorporated useful parameter features into the pipeline such as, handling variable-length read data, and searching spliced sequences for splicing signatures and miRNA events. We suggest RSF, a tool for identifying novel splicing events, is applicable to study a range of diseases across biological systems under different experimental conditions. Electronic supplementary material The online version of this article (10.1186/s12859-017-1801-y) contains supplementary material, which is available to authorized users.


Background
Alternative splicing (AS) is an important posttranscriptional process enabling a single gene to generate multiple different transcripts, also called isoforms [1,2]. AS can increase the proteome diversity as well as modulate the stability of mRNAs by means of downstream RNA quality control (QC) mechanisms, which include nonsense-mediated decay (NMD) of the transcripts that possess premature termination codons and nuclear retention and elimination (NRE) of transcripts that contain introns [3]. In eukaryotes, the AS process removes introns from the nuclear pre-mRNAs with the help of the spliceosome, which can recognize conserved short consensus sequences within the introns and at intron-exon boundaries. More specifically, conserved dinucleotides located at the first two and the last two positions of introns in the pre-mRNAs are recognized by the spliceosome [4].
In higher eukaryotes, there are two types of identified spliceosome complex that catalyze the pre-mRNA splicing [5]. The majority of pre-mRNA introns (U2-type introns) are excised by the U2-dependent, major spliceosome that is found in all eukaryotes, whereas approximately 0.35% of human introns (U12-type introns) were removed by the U12-dependent, minor spliceosome that is found in only a subset of organisms [6][7][8]. Approximately 700 to 800 genes containing U12-type introns were identified in the human genome [9]. Unlike U2type introns, the U12-type introns lack a polypyrimidine tract that is located upstream of the 3′ splice site (ss) however, the U12-type introns have highly conserved sequences located at their 5′ ss as well as branch sites [6]. It was found that, within the same gene, the U12-type introns co-occur with the U2-type introns, but the U12type introns are spliced more slowly, suggesting the role of U12-type splicing in a rate-limiting step in gene expression [10]. The U12-dependent spliceosome is composed of the U11, U12, U4atac, and U6atac snRNPs, which are the functional homologs of the U1, U2, U4, and U6 in the U2-dependent spliceosome, respectively. Both U2-type and U12-type spliceosomes have the U5 snRNP [5,8]. Although U2-type and U12-type spliceosomes have most of their protein components shared, seven protein components are unique and associated with the U11/U12 di-snRNP so that the U11/U12 di-snRNP can recognize the branch point sequences and the 5′ splice sites of the U12-type introns [8].
Mutations in the U12-type spliceosome, either in specific snRNA or in protein components, can cause diseases of very narrow tissue-specific consequences [11,12]. Three patients possess severe isolated growth hormone deficiency (IGHD) and pituitary hypoplasia that arise from the biallelic mutations in the RNPC3 gene that encodes the 65 kDa protein component of the U12-type spliceosome [12]. Mutations in specific regions in the U4atac snRNA cause microcephalic osteodysplastic primordial dwarfism type I (MOPD I), also called Taybi-Linder syndrome (TALS). The mutations most probably result in distortion of the phylogenetically conserved stem-loop (SL) structure formed by U4atac snRNA. The distortion prevents the normal binding of a 15.5 K protein component of the spliceosome to the SL structure, thereby causing a series of downstream consequences, and eventually accumulating the immature pre-mRNAs that carry unspliced U12-type introns [13].
MicroRNA (miRNA) are small, non-coding RNA that serve as genetic regulatory elements in animals by silencing, and in rare cases enhancing, other mRNA transcripts. These single-stranded RNA are approximately 22 nucleotides in length and are involved in many processes throughout the body [14,15]. These small mature miRNA are processed from longer pre-miRNA. Pre-miRNA forms a stem and loop structure that is processed by two RNase III enzymes: Drosha and Dicer [16]. Regulation mediated by miRNA targets mature mRNA in the cytoplasm, the miRNA will bind to the 3'UTR of the target mRNA. This binding can help to stabilize the targeted transcript but is usually followed by the interaction with RISC complex which leads to degradation of the mRNA, by this process miRNA is able to effectively silence the translation of its target [17]. Beyond degradation, miRNA also physically impairs the binding of the mRNA to the ribosome [14,15]. It is estimated that more than 60% of all protein coding genes are regulated by miRNAs by these methods [18]. As such, miRNA has been implicated in many different complex diseases.
These diseases include many cancers, neurological diseases, cardiovascular disease, and other inheritable diseases. In cancer miRNA expression profiles have been well documented with many differences in expression between normal and tumor tissue. Typically this is shown by an overall downregulation of miRNA in tumor tissues [19]. miRNAs are able to act as either tumor suppressor genes or oncogenes depending on the targets of the specific miRNA [20][21][22][23]. The development of neurons is highly influenced by the presence of miRNA [24]. As such, the misregulation of miRNA has been implicated in Parkinson's disease, Alzheimer's disease, Down's syndrome, and many other diseases [25][26][27][28][29][30][31][32][33]. The involvement of miRNA in cardiovascular diseases is similar to their involvement in neurological diseases -changes in miRNA expression can lead to arrhythmias, vascular abnormalities, unrestricted muscular growth, hypertension, and can lead to death if completely removed [34][35][36][37][38][39][40][41][42]. Other diseases that have been associated with miRNA include 5q syndrome, ICF syndrome, Rett's syndrome, Crohn's disease, and even deafness [43][44][45][46][47][48]. With the implications of miRNA in a multitude of complex diseases they have become important for targeted therapies and potential indicators of these diseases making them an important target for further study.
Given that such types of non-canonical splicing events of short mRNA regions and U12-type intron are important across biological systems and diseases, there is an urgent need to develop methodologies for identifying all possible non-canonical short splicing regions in cytoplasm and also looking for U12-type spliced isoforms. Most existing tools for detecting next-generation sequencingbased splicing events focus on generic splicing events. Consequently, non-canonical splicing events of short mRNA regions occurring within the cytosol and U12-type events have not yet been thoroughly investigated using bioinformatics approaches in conjunction with nextgeneration technologies at a genome-wide level.
We have developed a novel bioinformatics pipeline method named the Read-Split-Walk (RSW) [49] and Read-Split-Run (RSR) [50] for detecting non-canonical, short, splicing regions using RNA-Seq data. In this study, we have advanced the algorithm with an improved running speed and memory usage. We have applied RSF on human ENCODE data to characterize U12 splicing and study miRNA signatures in spliced sequences.

RSF pipeline
The presence of novel isoforms by splicing independent of normal mRNA processing has previously been identified by the Read-Split-Walk (RSW) pipeline developed in 2014 [49] and Read-Split-Run (RSR) [50]. Here we developed an updated version of RSF: Read-Split-Fly. This enhanced RSF has a newly developed pipeline with improved performance, sensitivity, and flexible parameter features. This pipeline has achieved a reasonable specificity (>60%) of novel junctions for the half of tested ENCODE samples and high specificity for detection of both known and novel junctions for ¾ of tested ENCODE samples, with some samples having as high as 98% specificity (Fig. 1). The lower bound of the sensitivity of RSF was calculated using the UCSC refFlat file, this resulted in a total of sensitivity across all samples tested (39%) with a maximum sensitivity of 90% (Fig. 2a). Calculating the sensitivity only for genes with a single isoform and detected by RSF resulted in a slightly higher sensitivity calculation overall (Fig. 2b). An analysis was also performed for genes grouped by RPKM. As expected, RSF has a much higher sensitivity in detecting high RPKM genes than those with a low RPKM (Fig. 2a-c).

Comparison of detected spliced regions between RSR and RSF
RSR and RSF were both run on the same 70 samples from the ENCODE dataset in order to compare their performance and sensitivity. The efficiency of RSF over RSR is evident in the amount of memory and CPU time that each sample requires to complete its run. RSF showed an average of four-fold decrease in needed CPU time and a threefold decrease in the required memory ( Fig. 3 and Additional file 1). Along with improvements in the efficiency of the program, RSF is able to detect more spliced regions than RSR. RSF can detect 6% more spliced regions than RSR reports as well as more unique junctions ( Table 1).

The spliced regions detected by the RSF pipeline for human ENCODE data
The RSF pipeline was used to identify spliced regions that exhibit different signature in cancer versus normal samples from the ENCODE dataset. The analysis was performed using 28 cancer samples and 42 normal samples from ENCODE (Additional file 1). Two hundred ninety-seven spliced regions were found to occur in a higher percentage (greater than 50% difference) of cancer samples than normal samples; of these, 26 were detected within at least 55% of the cancer tissue samples, with the greatest occurrence being 86%. These were further classified by their specific tissue type. Specifically, all of them were found in samples associated with the adenocarcinoma and breast cancer, and some subset of the same 297 junctions were found in the other types of cancer (Table 2). Six hundred eleven unique splice junctions were found that occurred in a much higher percentage (greater than 50% difference) of normal samples than cancer samples; of these, 168 were detected within at least 55% of the normal tissue samples (Additional file 2). These results are based on the normalized comparison. These shared splice junctions show great potential for further analysis of their importance in the development of these specific cancers and in general tumor formation.

The downstream analysis for spliced sequences of RSF algorithm
Using various splicing categories of downloaded U12 and U2-type intron queries against the junctions as queries, we blasted the queries against the splice junction sequences reported by RSF from 70 ENCODE samples. We found that U2-type intron hits are much more than the U12-type hits, consistent with the major proportion of U2-type introns and minor proportion of the U12-type introns. The 5p_full queries got less hits than the 3p_full queries in both U12 and U2 type introns. Interestingly, both U12-type and U2-type intron 5p_full queries hits more novel splicing junctions relative to the known splice junctions, whereas both U12-type and U2type 3p_full queries hits less novel splicing junctions relative to the known splice junctions. We also observed that there are more U12-type than U2-type for 5p_full category (Table 3). We didn't have branch queries for U2, which were not listed in the U12DB website [51].
For the spliced junctions found by RSF in 70 human ENCODE samples, the spliced sequences were exported for further analysis. Homo sapiens miRNA sequences were downloaded, and a custom shell script was written to run BLAST to report the number of hits of each miRNA sequence within each ENCODE spliced sequence. The total number of hits of each miRNA sequence over spliced sequences from all 70 ENCODE samples is reported in Fig. 4 and Additional file 3. Two hundred twenty-one miRNAs have at least 1 hit among the spliced sequences from 70 ENCODE samples. Seven miRNAs hits were seen within the spliced sequences of at least 30 out of 70 ENCODE samples. Of these seven, hsa-miR-1273d, hsa-miR-548aa, hsa-miR-548 t-3p, and hsa-miR-1273 g-3p have known associations with different cancer types. The cancer association results are summarized in Table 4.

Parameter consideration in RSF pipeline
Several parameters allow the user to customize RSF output, but have little effect on the time or resources needed to execute the pipeline. These include MODE and SUPP. MODE must be "analytic" or "comparison". Single datasets are run in analytic mode. Comparison provides a side-by-side comparison of common and unique splice junctions in addition to the standard output for each dataset. Any potential splice junction site must carry a minimum of SUPP supporting reads to be reported.
The MIN_D and MAX_D parameters control the minimum and maximum distance for which split reads are reported by RSF. In general, larger values may increase both sensitivity and the running time of the pipeline. MAX_ALIGNMENTS determines the number of alignments before a read or partial read is ignored due to having too many alignments. A higher value may increase sensitivity and running time. MIN_SPLIT_SIZE determines the smallest length that a read is split into for mapping to the reference genome. A lower value increases sensitivity and running time. Running time can be made quite small for test runs by setting both MAX_D and MAX_ALIGNMENTS very low and MIN_-SPLIT_SIZE very high (e.g., 10,000, 2, and just under half of the original read length, respectively).

Disk utilization of our RSF algorithm
For each RNA-Seq read that originally fails to align to the reference genome, there is a quadratic increase in storage requirements which scales relative to the minimum split size selected. With a minimum split size of 11 nt selected, a relatively small FASTQ file containing 7.8 million

RSF running speed, sensitivity, and specificity
With these improvements RSF produces results for larger datasets in much less time allowing for more data to be processed and a better and more thorough understanding of potential novel splice junctions. RSF also can process RNA-Seq files containing variable-length reads, which makes our software be more flexible in handling data generated from Ion Torrent sequencer. The low sensitivity of certain files was directly correlated with the number of junctions that were reported by RSF as well as the RPKM. Genes with a low RPKM had much lower sensitivity (31%), while those with a high RPKM showed a much higher total sensitivity (82%) (Fig. 2c). Sensitivity calculations can be artificially low for genes with many isoforms that are not expressed. For genes with only a single isoform in the UCSC ref.
-flat file, the sensitivity of RSF ranged from 39% for low RPKM genes to 93% for genes with high RPKM (Fig. 2b-c). Conversely, the specificity for RSF to accurately detect all junctions and novel junctions are relatively high. Overall, RSF is able to detect many possible junctions (especially those with a high RPKM) with very high overall accuracy and rather high accuracy for novel junctions.

Applying RSF on human ENCODE RNA-Seq data
The splicing events identified by RSF on the 70 human ENCODE samples used for this project, yielded many potential avenues for further research. The novel splice junctions (Additional file 2) are especially of great interest. These splicing events were present in cancerous tissues making the transcripts and their potential protein products good candidates for the study of cancer development. Because of their novel nature, the impact of these splicing events cannot be ascertained at this moment, but we are hopeful in the impact of the discovery of these and many more using RSF. The previously known splicing events are also an interesting avenue of research as they are still expressed differently between cancerous and normal tissue. It is also interesting to note the distribution of shared splicing events, the normal tissue has the most shared splicing events around a quarter of all samples and quickly tapers off from there (Fig. 5). The cancerous samples however, have two notable maxima, one at 0.3 and another at 0.55, making the curve taper at a much steadier rate. From this we can reasonably conclude that the cancerous tissue seems to have a greater number of shared sequences for a higher percentage of its samples (Fig. 5).

Conclusions
We have developed an improved RSF pipeline that can detect novel splicing events with better performance and accuracy when compared to previous RSW and RSR methods. Our RSF allows flexible parameters and can process large number of samples in a memory efficient manner.

Methods
The reference genome for Read-Split-Fly The RSF program uses the Homo sapiens GRCh37/hg19 genome as its reference for all bowtie related alignment and splice junction detection. This genome is freely available for download from the University of California Santa Cruz Genome browser [52].

Read-Split-Fly Algorithm
RSF shares the same basic framework that was developed in earlier work [49,50]. In brief, (i) short reads of RNA-Seq data are mapped to a reference genome with the bowtie aligner, (ii) unmapped reads are split at various points, (iii) the read parts are mapped to the reference genome, (iv) mapped parts that are from the same original read and map within the same gene are called a matched pair, and (v) all matched pairs are compared to determine which support each other and which splice junctions have a high amount of support. See [50] for more details on the basic framework. RSF has a number of key improvements over the earlier RSR and RSW pipelinesallowing files with variable length reads, improved speed and memory efficiency, increased sensitivity, and incorporation of downstream analysis. The entire pipeline is updated so input files can contain reads of variable length; this is done by modifying each part of the code to take the read length into account (previously the read length was a parameter fixed during the processing of a given input file). The calculation of supporting reads is performed in a faster and more memory-efficient manner. Speed and memory usage are improved by sorting candidate splices by both ends of the splice and processing all matched pairs in a given region of the genome at once.
Sensitivity is improved in the pipeline by taking into account sub-sequences of unmapped reads that do not result in any matched pair. Unmapped reads are split into two parts (a left and right side) and aligned to the reference genome. In some circumstances, one part aligns to many locations; for example this occurs if one side is very short (e.g., if the read is split into left side of length 8 and right side the remaining nucleotides). In these situations, both RSR and RSF ignore the part that aligns to many locations for reasons of efficiency. RSF rescues these reads by including the remaining longer side of the read when computing supporting reads of matched pairsalignments of the long side of reads that have no matched pairs are compared against candidate splices, and are counted as supporting a matched pair if the longer side aligns with one end of the splice.
The RSF pipeline includes the option of including downstream analysis by searching databases of U12 and U2- type splice sequences and miRNA sequences within the splices found by the pipeline, as described further below.

Methods of running Read-Split-Fly on human ENCODE dataset
Using RSF over 150,000 unique splice junctions were detected within the ENCODE data sets downloaded from the encode website [53] (https://www.encodeproject.org/). Most of these junctions were shared by another, or by many other, samples within the 70 samples studied for this project. Within this data set 42 samples were collected from normal tissue and 28 samples were from cancerous tissue. Of these tissues 4 were from neuroblastoma, 3 from cervical cancer, 3 from breast cancer, 8 from adenocarcinoma, and 9 from leukemia samples. The final sample of the cancer set was from a liver tumor but was left out of analysis as it lacked any replicates. In order to better classify the splicing events with the most potential for further analysis we further classified splicing events by the difference in the frequency with which they appear in the normal versus cancer samples, allowing for a pseudo-differential expression analysis of these splicing events. For our study we focused on the samples that had over 50% difference occurrence for cancer versus normal samples. RSF initially aligned the RNA-Seq reads to the hg19 reference genome using the bowtie sequence aligner, version 1.0.1 [54], with the arguments "-p 7 -n 3 -e 112 -un". These parameters specify the use of 7 threads (−p 7), allow 3 mismatches in the first 28 bases on the high quality end of the read (−n 3), and stipulate that the sum of the Phred quality values across all mismatched positions in the read must not exceed 112 (−e 112). In this step we are interested in reads that do not initially match (−-un).
The RNA-Seq reads in the ENCODE samples we have processed with Read-Split-Fly at this time vary in length from 34 to 101 nt. We selected the minimum split length for each experiment based on the length of the original read (15 nt if <75, 30 nt if ≥75).
These lengths were chosen to balance the resources needed to execute the pipeline with the sensitivity of support for potential splice junction sites.
RSF then aligned these reads with bowtie using parameters "-p 7 -best -m 2 -k 2 -v 0". We allowed no mismatches (−v 0) and suppressed all alignments if more than 2 alignments are reported (−m 2). With the -v 0 mode, the -best argument instructs bowtie to attempt 800 backtracks instead of the default 125.
RSF next calculated the number of supporting reads at each splice junction site. Potential junction sites are only reported if the splice is between 2 and 50,000 nt long and has at least 2 supporting split reads. For these experiments, we configured RSF to allow for two split reads to support each other if the corresponding left and right ends align within 5 nt of each other. This allows reporting splice junction sites even when there exists reference genome ambiguity due to repeated nucleotide sequences.
BLAST the U12DB introns and miRNABase miRNAs against the splice junction sequences found by RSF The miRNA sequences were downloaded from the miRBase websites [55][56][57][58][59][60] (http://www.mirbase.org/) Release 21. U12-type and U2-type introns were downloaded from the U12DB website [51] (http://genome.crg.es/cgi-bin/u12db/u12db.cgi), and listed in Additional file 4. The downloaded U12-type and U2type intron sequences were processed and classified into different categories as queries in the next BLAST step. The customized SQL script was written to retrieve U12-type and U2-type sequences. The categorized query files are delineated in Table 5 and Fig. 6. The logos of the Fig. 6 are adapted from Padgett [61].
A custom C program was written to process the categorized U12-type and U2-type introns and miRNA sequences into FASTA format files. We used BLAST [62] to identify the regions of similarity, using the foregoing categorized U12-type introns, U2-type introns, or

Calculation of sensitivity and specificity
Both specificity and sensitivity are calculated for the junctions found by RSF for each of 70 ENCODE samples. Specificity and sensitivity are calculated for the detected junctions following the metrics: 1) Specificity for RSF detected novel junctions (number of RSF detected novel junctions that are validated by EST/ number of RSF detected novel junctions); 2) Specificity for RSF detected junctions (number of RSF detected junctions that are validated by EST/ number of RSF detected junctions); 3) Sensitivity for RSF detected known junctions (number of RSF detected known junctions/ number of UCSC refFlat file possible junctions of genes present in RSF detected known junctions).
The expression sequence tag (EST) is the standard to determine whether detected junctions, novel and/or known, are supported by experimental validation. The EST data [63] is downloaded from the UCSC table browser (http://genome.ucsc.edu) with the following parameters: clade = Mammal, genome = human, assembly = Feb.2009(GRCh37)/hg19, group = All Tracks, track = human ESTs, table = all_est, region = genome, output format = GTFgene transfer format [52] A detected junction is considered to be validated by EST if its left boundary is overlapped with at least one EST end within 5 bp size buffer to the left and the right, and its right boundary is overlapped with at least one EST start within 5 bp size buffer to the left and the right. EST was calculated for each ENCODE sample processed by RSF (Fig. 1).
The sensitivity calculations were performed both for all genes with junctions detected by RSF (Fig. 2a), and  Table 5 The categorized U12-type and U2-type introns as queries and their stretch of the sequence included Authors' contributions YB designed and supervised the project, performed the analysis, provided biological interpretation, and wrote the manuscript. JK supervised the project, wrote the software code, performed the analysis, and wrote the manuscript. LD ran the pipeline, wrote the manuscript, and prepared tables and figs. ER and AC participated in result comparisons between RSF and RSR, and wrote the manuscript. ER also prepared tables and figures and provided biological interpretation. AC also wrote software code, tested RSF parameters, and ran the pipeline. SN wrote BLAST pipeline code and prepared tables. All authors read and approved the final manuscript.